– USA, CA – Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, today announced the appointment of Dr. Steve Mayo (Ph.D.) to its Board of Directors.
“We are privileged to have Dr. Mayo join our Board of Directors. His decades-long success record in both academia and the biopharmaceutical industry will serve Allogene well as we look to progress our pipeline of investigational AlloCAR T products to deliver readily available cell therapy faster, more reliably, and at greater scale to more patients,” said CEO and Co-Founder, Dr. David Chang.
About Dr. Stephen L. Mayo
Dr. Mayo is the Bren Professor of Biology and Chemistry and Merkin Institute Professor at Caltech in Pasadena, California. He served as Vice-Provost for Research at Caltech from 2007 to 2010 and Chair of its Division of Biology and Biological Engineering from 2010 to 2020.
“Allogene’s experienced management team, deep allogeneic CAR T pipeline, scientific excellence, and in-house cGMP manufacturing capability have created a remarkable foundation to support the rapid advancement of its pipeline,” said Dr. Steve Mayo. “The company’s leadership in allogeneic CAR T therapy is unmatched and I am honored to join the Allogene Board.”
Dr. Mayo also serves on the Board of Directors of Merck & Co and Sarepta Therapeutics, Inc. Dr. Mayo co-founded Molecular Simulations, Inc. (currently Accelrys/Biovia), a computational chemistry company; Xencor, Inc., a publicly-traded bio-therapeutics company focused on developing next-generation biologics for treating cancer; and Protabit, LLC, a privately held protein engineering company focused on the use of artificial intelligence and machine learning for protein engineering applications. In addition, he serves on the scientific advisory boards of Vida Ventures, Rubryc Therapeutics, and Evozyne. Dr. Mayo was elected to the National Academy of Sciences in 2004 for his pioneering contributions in the field of protein design. He served as an elected board member for the American Association for the Advancement of Science from 2010 to 2014 and as a presidential appointee on the National Science Foundation’s National Science Board from 2013 to 2018.
Dr. Mayo holds a B.S. in Chemistry from Pennsylvania State University and a Ph.D. from Caltech. He completed postdoctoral work at both UC Berkeley and Stanford University School of Medicine in chemistry and biochemistry, respectively.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell candidates to deliver readily available cell therapy on-demand, more reliably, and at a greater scale to more patients.
For more information: https://www.allogene.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
